TLDR
- Pfizer stock trades near $26.78 as EMA accepts its Lyme vaccine application.
- Pfizer’s Lyme vaccine showed more than 70% efficacy in the Phase 3 VALOR trial.
- EMA validation starts the formal review process for Pfizer’s Lyme vaccine candidate.
- Pfizer and Valneva target a disease affecting over 100,000 Europeans each year.
- PF-07307405 could become Europe’s first approved human vaccine against Lyme disease.
Pfizer (PFE) stock traded almost flat in pre-market trading after European regulators accepted its Lyme disease vaccine application. PFE traded at $26.78, down 0.07%, after closing the previous session at $26.80. The regulatory milestone follows encouraging Phase 3 results showing vaccine efficacy above 70%.
Pfizer Stock Gets Regulatory Boost From EMA Validation
Pfizer and Valneva said the European Medicines Agency validated their Marketing Authorization Application for PF-07307405. The validation allows the EMA to begin formally assessing the companies’ experimental Lyme disease vaccine. Pfizer would manufacture and commercialize the vaccine if regulators eventually approve the candidate.
The application includes results from the Phase 3 VALOR study involving participants aged five years and older. Researchers tested whether PF-07307405 could prevent Lyme disease among people exposed through outdoor activities. The companies reported efficacy above 70%, while the trial identified no major safety concerns.
The development adds another regulatory catalyst to Pfizer’s vaccine portfolio after several years of shifting pharmaceutical demand. However, PFE showed limited pre-market movement despite the European regulatory update. Shares remained around $26.80, reflecting relatively muted immediate market activity following the announcement.
Pfizer Lyme Vaccine Targets Major European Health Burden
Lyme disease remains the most common vector-borne illness across Europe and affects more than 100,000 people annually. More than 200 million Europeans also live within regions where Lyme disease exposure remains a recognized risk. Untreated infections can affect joints, skin, the nervous system and the heart.
PF-07307405 targets outer surface protein A, known as OspA, which appears on Lyme disease-causing Borrelia bacteria. Vaccination encourages the body to produce antibodies against six common OspA serotypes. Those antibodies can block bacterial transmission when infected ticks feed on vaccinated people.
The candidate covers major Borrelia strains found across Europe and North America. Pfizer and Valneva have completed two pivotal Phase 3 studies evaluating efficacy, safety, immunogenicity, and manufacturing consistency. No human Lyme disease vaccine currently holds regulatory approval in either market.
Pfizer and Valneva Advance Long-Term Vaccine Partnership
Pfizer and Valneva began their Lyme vaccine partnership through a collaboration and licensing agreement signed in April 2020. Both companies have since shared development responsibilities for the experimental vaccine program. Pfizer holds exclusive manufacturing and commercialization rights under the agreement following successful regulatory approval.
The EMA validation represents an important step, although regulators still need to complete the full scientific review. The assessment will examine clinical effectiveness, safety findings, manufacturing quality, and the vaccine’s overall benefit-risk profile. A positive decision could establish PF-07307405 as the first available human Lyme disease vaccine in Europe.
For Pfizer, approval could expand its vaccine business while addressing a disease with substantial exposure across several European countries. The program also gives Pfizer another late-stage product following years of research investment with Valneva. PFE’s next market reaction could depend on regulatory progress and further details surrounding the commercial opportunity.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
